AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05997251 — intervention group
Intervention type: OTHER
Intervention: Keeping a 1-day food consumption record by the patient
Description: Checking and receiving the 1-day food consumption record recorded by the patient by the researcher
Study NCT05997251 — intervention group
Intervention type: OTHER
Intervention: Measurement of adiponectin level
Description: Adiponectin level will be measured for each group
Study NCT06452186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: direct EMG controlled prosthetic ankle
Description: Patients are trained to use the powered prosthetic ankles
Study NCT06452186 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PT guided prosthetic training
Description: Amputees are trained to use prosthetic ankles
Study NCT06452186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PT guided prosthetic training
Description: Amputees are trained to use prosthetic ankles
Study NCT05552209 — intervention group
Intervention type: DEVICE
Intervention: Elbow MID 500
Description: 15 patients will be included in this group and will used the medical device Elbow MID 500 during sport practice (at least 2 sport sessions per week), for 6 weeks.
Study NCT05552209 — intervention group
Intervention type: OTHER
Intervention: Control group Elbow MID 500
Description: 15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device Elbow MID 500), for at least 2 sport sessions per week during 6 weeks.
Study NCT05552209 — intervention group
Intervention type: DEVICE
Intervention: Elbow STRAP
Description: 15 patients will be included in this group and will used the medical device Elbow STRAP during sport practice (at least 2 sport sessions per week), for 6 weeks.
Study NCT05552209 — intervention group
Intervention type: OTHER
Intervention: Control group Elbow STRAP
Description: 15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device Elbow STRAP), for at least 2 sport sessions per week during 6 weeks.
Study NCT04951401 — intervention group
Intervention type: OTHER
Intervention: lipid profile
Description: lipid profile
Study NCT04951401 — intervention group
Intervention type: OTHER
Intervention: ECG
Description: ECG
Study NCT04732533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation)
Description: Phase 1: The participant will receive 10, 20-minute sessions of tDCS on Monday-Friday, at approximately the same time of day, over two consecutive weeks.~Phase 2: The participant will receive 22, 20-minute sessions of tDCS. 10 sessions will take place over the first two weeks on Monday-Friday, at approximately the same time of day. This will be followed by 3 tDCS sessions per week over four weeks.~Phase 3: The participant will receive up to 260, 20-minute sessions of tDCS. The participant can complete up to 5 tDCS sessions per week over 52 weeks.
Study NCT05965661 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: virtual reality upper limb hand training
Description: The PD patients randomized in the experimental group will receive virtual reality upper limb hand training.
Study NCT05965661 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: virtual reality control training
Description: The PD patients randomized in the control group will receive virtual reality control training.
Study NCT05266586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: tablets
Study NCT05266586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg
Description: capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.
Study NCT05266586 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Obicetrapib placebo
Description: tablets; no active ingredient
Study NCT05266586 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe placebo
Description: capsules; no active ingredient
Study NCT05266586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ezetimibe placebo
Description: capsules; no active ingredient
Study NCT06073379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Korean manupuncture
Description: Energy assessment on hands and body Correspondence point technique on hands Energy rebalancing with ki Maeks on hands Moxa technique on hands
Study NCT06073379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo session
Description: Energy assessment on hands and body Correspondence point technique on the hands Energy rebalancing with ki Maeks on hands (use of Qi bong) Moxa technique on hands (placebo moxas)
Study NCT05137860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.
Study NCT06211335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Given PO
Study NCT06211335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT06211335 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT04531215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Retrolaminar Block
Description: ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side
Study NCT04531215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Erector Spinae Plane
Description: ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
Study NCT05923957 — intervention group
Intervention type: OTHER
Intervention: TENS and Exercise
Description: High frequency electrical stimulation was done for thirty minutes per day for five days a week for four consecutive weeks. The stimulator provides a biphasic current of 100 Hz frequency. The pulse duration was 200 msec with an (on-off). Stimulus mode (20sec stimulation, 20 sec pause). The maximal stimulation amplitude was 40 - 60 mA
Study NCT04724226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab; Apatinib
Description: Cryoablation~Drug: Camrelizumab and Apatinib Camrelizumab (200mg), iv, Q3W; Apatinib (250mg), po, QD
Study NCT04805554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint Insights decision aid
Description: The Joint Insights decision aid was developed by Dell Medical School faculty in collaboration with OM1, a health outcomes and predictive analytics company. This decision aid uses patient-report outcome measures (PROMs) - specifically, the PROMIS Global and the KOOS JR - along with patient clinical and demographic information (age, sex, race, ethnicity, chronic narcotic use, body mass index), in machine-learning-based predictive analytic models to provide personalized estimates of likely benefit or harm from total knee replacement surgery. The tool is designed to collect PROMs or pull in PROMs collected through other systems (e.g., an EHR or a third-party PROM platform). It also provides condition-specific education to patients with knee OA and allows a patient to reflect on and document their preferences and goals. The personalized risk/benefit report generated by the decision aid is meant to be discussed with the patient's provider to enhance shared decision making.
Study NCT04805554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint Insights decision aid
Description: The Joint Insights decision aid was developed by Dell Medical School faculty in collaboration with OM1, a health outcomes and predictive analytics company. This decision aid uses patient-report outcome measures (PROMs) - specifically, the PROMIS Global and the KOOS JR - along with patient clinical and demographic information (age, sex, race, ethnicity, chronic narcotic use, body mass index), in machine-learning-based predictive analytic models to provide personalized estimates of likely benefit or harm from total knee replacement surgery. The tool is designed to collect PROMs or pull in PROMs collected through other systems (e.g., an EHR or a third-party PROM platform). It also provides condition-specific education to patients with knee OA and allows a patient to reflect on and document their preferences and goals. The personalized risk/benefit report generated by the decision aid is meant to be discussed with the patient's provider to enhance shared decision making.
Study NCT05052554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-504a
Description: Intravitreal (IVT) injection
Study NCT05843188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Anti-Inflammatory - antimalarial - aminoquinolines
Study NCT05843188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Antineoplastic agent
Study NCT05843188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Antineoplastic agent
Study NCT05843188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Folic acid derivative
Study NCT05843188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Folic acid derivative
Study NCT05843188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Antineoplastic agent
Study NCT05843188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Antineoplastic agent
Study NCT05843188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Antineoplastic agent
Study NCT05843188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Antineoplastic agent
Study NCT04824521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement
Description: MORE is a mindfulness-based intervention.
Study NCT04822012 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anti COVID19 IgG Antibodies
Description: Detection of antibodies to SARS Cov 19 post infection or vaccination , measurements of female hormones in folicular fluid as compared to serum and Perlecan as a follicular quality marker
Study NCT06200831 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged resection
Description: Patients randomized to staged resection will be operated according to the decision made by the tumor board meeting (liver or colorectal cancer first, based on tumor burden and symptoms), but both resections have to be done within a time period of 4-12 weeks.
Study NCT06200831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneous resection
Description: In cases with simultaneous surgery, the liver resection is performed prior to colon resection in order to keep a low central venous pressure during the first part of the surgical procedure and to avoid congestion of the anastomosis line owing to possible Pringle manoeuvre.
Study NCT04687228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More than Muscles (MTM)
Description: In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal.
Study NCT04687228 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Media Advocacy (MA)
Description: MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.
Study NCT05077865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYMD-1
Description: 150 mg capsule
Study NCT05077865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching in appearance to MyMD-1 150mg capsule
Study NCT04674670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine Mesylate Capsules
Description: Healthy controls and fibromyalgia patients will be administered a single dose of bromocriptine (1.25mg, p.o.) to investigate the effect of transiently increasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
Study NCT04674670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride 400 MG
Description: Healthy controls will be administered a single dose of amisulpride (400mg, p.o.) to investigate the effect of transiently decreasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
Study NCT04674670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Healthy controls and fibromyalgia patients will be administered a placebo as for comparison with the effects of bromocriptine (healthy controls and patients) and amisulpride (healthy controls only) on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
Study NCT05660577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens
Description: new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens
Study NCT04575948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moringa Oleifera
Description: Non toxic Moringa extract with antibacterial and antiplaque effect will be used
Study NCT04575948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Commercial 0.12% chlorhexidine digluconate mouthwash twice daily (each morning and before bedtime during the 21-day study period) after intake of food. The patient will be asked to use 15 ml of mouthwash swish it for 60 sec. then expectorate.
Study NCT04575948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Base formula
Description: Base formula is a negative control
Study NCT05967507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope
Description: 0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
Study NCT05967507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope
Description: 2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen (Fisher \& Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
Study NCT05408741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Intervention Group
Description: Participants will complete a 20-minute guided imagery exercise (which includes deep breathing exercises) every day at home using the selected app and/or resource you downloaded at the beginning of this study.
Study NCT05408741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Control Group
Description: Participants will continue to receive your current care, but will not receive guided imagery or deep breathing exercises from a social worker.
Study NCT06499064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mHealth
Description: Follow-up and treatment of patients in the mHealth arm will be based on a comprehensive solution for the care and monitoring of chronic patients, modelled and tested in chronic HF patients. This is the PIRENe platform, previously described and evaluated in HF patients. It is a digital solution, external to the centre's information systems (external platform). However, it has some special features in its design in terms of remote monitoring, educational tools, among others, expressly conceived and designed for patients with ATTR-CM. This platform allows the provision of multichannel service and monitoring of patients through:~1. Patient monitoring of: Biometric data and symptom report.~2. Generation and management of warning alarms notified to the professionals assigned to each patient in case one of the following situations occurs.~3. Follow-up via videoconference.
Study NCT05988554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: Consume 1 sachet daily
Study NCT05988554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa extract and collagen products
Description: Consume 1 sachet daily
Study NCT05680064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tongue, lip, chin exercise group
Description: In order to evaluate the effect of chewing gum and tongue, lip and chin exercises on salivary flow rate, xerostomia and dysphagia, both intervention groups will work in a determined time frame daily.
Study NCT05997927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 tablets
Description: VC005 groups repeat administration for 12 weeks
Study NCT05997927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 Tablets Placebo
Description: VC005 placebo groups repeat administration for 12 weeks
Study NCT05997927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VC005 Tablets Placebo
Description: VC005 placebo groups repeat administration for 12 weeks
Study NCT04239716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regional anesthesia
Description: combination of erector spinae plane block and interscalene block for anesthesia in modified radical mastectomy surgeries with axillary lymph node dissection
Study NCT06108037 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Generative AI for electronic communication and disclosure
Description: We will use a large language model such as GPT 3.5 to automatically generate responses to fictional messages to a physician. We will disclose whether the message was generated using this technology or not. There are 3 clinical scenarios and 6 pairs of human/AI response and human disclosure/AI disclosure/not disclosed that will test patient attitudes toward this technology.
Study NCT04775589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Exercise for Knee Osteoarthritis
Description: Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps
Study NCT04531553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: Patients will preoperatively receive thoracic epidural at the level T5 \& T6 with bolus 20 ml of levobupivacaine 0.25% then levobupivacaine 0.1% infused at a rate of 0.1 mL/Kg/hr until chest tube removal ( 5-6 days).
Study NCT04531553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB with levobupivacaine and dexmedetomedine
Description: patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% plus 0.5mic/Kg dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted. 20 ml bolus of levobupivacaine 0.1% with dexmedetomidine 0.5 μg/Kg was injected every 6 hours until chest tube removal.
Study NCT04531553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB with levobupivacaine
Description: patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted.A 20 ml bolus of levobupivacaine 0.1% is injected every 6 hours until chest tube removal.
Study NCT06231966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy of high-intensity dose rosuvastatin and ezetimibe
Description: Combination therapy of rosuvastatin 20 mg and ezetimibe 10 mg
Study NCT06231966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin monotherapy for treat-to-target
Description: Rosuvastatin monotherapy for treat-to-target (LDL cholesterol \<70 mg/dL)